Jenny Yip

https://lnkd.in/etB2Pmqt : a new compound called TRanscriptional Activator of p53 (TRAP-1) is able to engage p53-Y220C and BRD4 in a ternary complex, which potently re-activates mutant p53, resulting in rapid upregulation of p21 and other p53 target genes and inhibits the growth of p53Y220C-expressing cell lines.

8

🧬𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐔𝐩𝐝𝐚𝐭𝐞𝐬 𝐈𝐧 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 🧬 REVEAL GENOMICS, S.L. unveiled TNBCDX® test Vizgen, Inc. announced the first global shipments of the MERSCOPE Ultra™ Platform Depixus launched of MAGNA One instrument Lexogen launched two products for single-cell RNA sequencing workflows PreAnalytiX GmbH launched a solution for liquid biopsy from urine samples Asimov launched the AAV Edge for payload design and gene therapy production RealSeq Biosciences offers RealSeq®-Biofluids small RNA library preparation kit for RNA samples derived low concentration samples Abbelight introduced the next generation of SAFe Platforms Singleron Biotechnologies launched the sCelLiVE® Tissue Dissociation Kit (Skin) Zetta Genomics Ltd announced that XetaBase is UKCA marked Mission Bio launched the Tapestri Genome Integrity CNV Solution CleanNA launched CleanNGS Dx reagent Applied DNA Sciences launches Mpox Clade I and Clade II testing service Dovetail Genomics launched its Certified Service Provider program and showcased new VariLink™ Assay findings Takara Bio Europe launched the Shasta Single-Cell NGS System BIOTYPE GmbH launched two additions to its Modaplex PCR-based assay portfolio Standard BioTools launched a new version of its SomaScan 11K assay 𝗧𝗵𝗲 𝗜𝗻𝗱𝗶𝗮𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗚𝗲𝗻𝗼𝗺𝗲 𝗔𝘁𝗹𝗮𝘀 launched a cancer multiomics data portal Genialis launched the krasID biomarker algorithm LGC Clinical Diagnostics launched ctDNA Mutation Mix v4 reference materials Cornerstone Genomics Inc. has launched the CodeExome platform 10x Genomics has launched the Chromium Xo QIAGEN launched 100+ new assays for its QiAcuity dPCR system SOPHiA GENETICS unveils new generation of the SOPHiA DDMTM platform MRC Holland launched an update to its SALSA DigitalMLPA Probemix D001 Hereditary Cancer Panel 1 Ambry Genetics updated its portfolio of tests to detect hereditary cancer mutations Variantyx launched Genomic Unity 2.0 diagnostic test Almaden Genomics launched a new data management & informatics services business Infinity Bio, Inc. launched its HuSIGHT-Total autoantibody analysis service Circular Genomics launched a PCR assay for SSRI antidepressant therapy Metabolon, Inc. launched an advanced statistical analysis tool Seegene Inc. launched two new RUO PCR assays for mpox clade I Ellison Institute of Technology launched EIT Pathogena Illumina released version 2.4 of its Correlation Engine software Ginkgo Bioworks, Inc. launched Ginkgo Automation Integrated DNA Technologies launched new HRD assays Bioneer’s AccuPower HIV-1 Kit gets WHO prequalification QIAGEN gets CE-IVDR Certification for for its QiaStat-Dx products Sysmex Inostics gets NYS CLEP approval for clinical trial use of liquid biopsy assay T2 Biosystems gets FDA clearance for it's diagnostic test for Candida for paediatric use Foundation Medicine gets FDA approval for tissue & liquid NGS CDx for Lynparza Combo 𝗙𝗮𝘀𝘁 𝗠𝗗𝘅 𝗟𝘁𝗱 gets CE-IVDR mark for NGX 124

96

3 Comments

Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation Programming cell signaling during T-cell activation represents a simple strategy for improving the potency of therapeutic T-cell products. Stim-R technology (Lyell Immunopharma) is a customizable, degradable synthetic cell biomimetic that emulates physiologic, cell-like presentation of signal molecules to control T-cell activation. A breadth of Stim-R formulations with different anti-CD3/anti-CD28 (αCD3/αCD28) antibody densities and stoichiometries were screened for their effects on multiple metrics of T-cell function. We identified an optimized formulation that produced receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeted chimeric antigen receptor (CAR) T cells with enhanced persistence and polyfunctionality in vitro, as assessed in repeat-stimulation assays, compared with a benchmark product generated using a conventional T-cell–activating reagent. In transcriptomic analyses, CAR T cells activated with Stim-R technology showed downregulation of exhaustion-associated gene sets and retained a unique subset of stem-like cells with effector-associated gene signatures following repeated exposure to tumor cells. Compared with the benchmark product, CAR T cells activated using the optimized Stim-R technology formulation exhibited higher peak expansion, prolonged persistence, and improved tumor control in a solid tumor xenograft model. Enhancing T-cell products with Stim-R technology during T-cell activation may help improve therapeutic efficacy against solid tumors. https://lnkd.in/ek8DUprH

41

Looking to achieve efficient recombinant AAV purification without a column?   A recently launched purification system provides an alternative to chromatographic affinity capture that eliminates the need for a nuclease treatment by using magnetic beads. These magnetic beads leverage the same affinity ligand as chromatography resin, offering high purity and yield in a single purification step, high specificity, high capacity, and improved process efficiency, and does not require a column.   Learn more about this tool and how it can help enhance your AAV downstream bioprocessing: https://lnkd.in/eCda3T6q   #bioprocessing #purification #viralvectors #chromatography #lifesciences

14

Looking to achieve efficient recombinant AAV purification without a column?   A recently launched purification system provides an alternative to chromatographic affinity capture that eliminates the need for a nuclease treatment by using magnetic beads. These magnetic beads leverage the same affinity ligand as chromatography resin, offering high purity and yield in a single purification step, high specificity, high capacity, and improved process efficiency, and does not require a column.   Learn more about this tool and how it can help enhance your AAV downstream bioprocessing: https://lnkd.in/eCda3T6q   #bioprocessing #purification #viralvectors #chromatography #lifesciences

11

Exciting advancements in bioprocessing! Discover how Repligen's #ProStream and #HyStream tangential flow filtration cassettes are enhancing efficiency and reliability in antibody-drug conjugate (ADC) production. These cutting-edge technologies offer superior performance, ensuring high-quality outcomes in complex ADC processes. Let's embrace innovation in biomanufacturing! #Bioprocessing #Innovation #ADC #Repligen

11

Learn how a DOE approach can support an upstream AAV platform that increases viral genome and full/empty capsid ratio. Register now: https://ow.ly/RAhL50TNkGh #SimplifyingProgress #InThisTogether #CellandGeneTherapy #AdvancedTherapies #CellTherapy #GeneTherapy

30

Keep pushing for breakthroughs! #GeneEditing #CRISPR #Knock_In #KnockOut #PointMutation #Overexpression #CellLineDevelopment #GeneticResearch #PrecisionMedicine #BiotechInnovation #CustomCellLines #MolecularBiology #ResearchTools #Genomics #EDITGENE #CrisprLibraryScreening https://lnkd.in/gE8age3i

1

"RF-amide peptides are a family of #Neuropeptides widely present in most animal phyla which display a great sequence diversity while sharing a conserved C-terminal RF-amide sequence. At present, five groups of RF-amide neuropeptides are identified in mammals. The #Neuropeptide 26RFa, a member of the RF-amide peptide family, activates the pyroglutamylated RF-amide peptide receptor (QRFPR), a class A G-protein-coupled receptor (#GPCR)! The 26RFa/QRFPR system plays critical roles in energy homeostasis, making QRFPR an attractive #DrugTarget for treating #Obesity, #Diabetes and eating disorders. However, the lack of structural information has hindered our understanding of the peptide recognition and regulatory #MechanismOfAction (MoA) of QRFPR, impeding #DrugDesign efforts!" Do not miss this amazing open-access article published in Nature Portfolio Cell Discovery this month, in which Yi Jiang from ShanghaiTech University and colleagues revealed the #CryoEM structure of Gq-coupled QRFPR bound to 26RFa: https://lnkd.in/eiYMbqAu The structure reveals a unique assembly mode of the extracellular region of the receptor and the N-terminus of the peptide and elucidates the MoA of the C-terminal heptapeptide of 26RFa by the transmembrane binding pocket of QRFPR. These findings deepen the understanding of the RF-amide peptide recognition aiding into the #RationalDesign of drugs targeting QRFPR and other RF-amide peptide receptors!

52

RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma In recent studies, we have established the unique adapter chimeric antigen receptor (CAR) platform RevCAR which uses, as an extracellular CAR domain, a peptide epitope instead of an antibody domain. RevCAR adapters (termed RevCAR target modules, RevTMs) are bispecific antibodies that enable the reversible ON/OFF switch of the RevCAR system, improving the safety compared to conventional CARs. Here, we describe for the first time its use for retargeting of both T and NK-92 cells. In addition, we describe the development and preclinical validation of a novel RevTM for targeting of the fibroblast growth factor-inducible 14 (Fn14) surface receptor which is overexpressed on Glioblastoma (GBM) cells, and therefore serves as a promising target for the treatment of GBM. The novel RevTM efficiently redirects RevCAR modified T and NK-92 cells and leads to the killing of GBM cells both in vitro and in vivo. Tumor cell killing is associated with increased IL-2, TNF-α and/or IFN-γ secretion. Hence, these findings give an insight into the complementary potential of both RevCAR T and NK-92 systems as a safe and specific immunotherapeutic approach against GBM. https://lnkd.in/eH-bdcw6

18

In a significant step for autoimmune disease treatment, Aditum Bio and Leads Biolabs have announced the launch of Oblenio Bio. This new venture aims to advance LBL-051, a groundbreaking tri-specific T-cell engager (CD19xBCMAxCD3) designed to reset immune responses in difficult-to-treat autoimmune disorders. What makes LBL-051 compelling is its potential for broad, durable efficacy by targeting multiple pathological B-cell markers, addressing an unmet need for more effective therapies. This partnership showcases the power of international biotech collaboration, with Aditum's innovation incubator model driving rapid clinical advancement and Leads Biolabs’ cutting-edge LeadsBody™ platform setting the stage for future breakthroughs. With up to $614 million in milestone payments and shared global development rights, this alliance is poised to accelerate solutions for patients worldwide. #Biotech #Pharmaceuticals #AutoimmuneDiseases #Innovation #GlobalPartnerships #LifeSciences #TylerLakeConsulting #ExecutiveSearch #ExecutiveRecruitment

4

Global Induced Pluripotent Stem Cell (iPSC) Industry Report – Market Size, Trends, & Forecasts, 2024 - https://lnkd.in/esH83uh Today, iPSCs are being utilized across a diverse range of applications, including: Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease. Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models “in a dish”. Drug Development and Discovery:iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery. Personalized Medicine: The use of techniques such as CRISPR enable precise, directed creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies is adding a new dimension to personalized medicine. Toxicology Testing: iPSCs can be used for toxicology screening, which is the use of iPSCs or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells. Tissue Engineering: iPSCs can be seeded onto scaffolds made from biocompatible materials. These scaffolds mimic the structure and properties of the target tissue and can provide a supportive environment for cell growth and differentiation. Organoid Production: iPS cells can be coaxed to self-organize into 3D structures called organoids, which mimic the structure and function of organs. Organoids can be used for studying organ development, modeling diseases, and testing drugs. Gene Editing: iPSCs can be genetically modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic changes. These edited iPS cells can then be differentiated into the desired cell type for transplantation or disease modeling. Research Tools: iPSCs and iPSC-derived cell types are being widely used within a diverse range of basic and applied research applications. Stem Cell Banking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors. Cultured Meat Production: iPSCs are being utilized in clean meat production by serving as the cellular foundation for the creation of lab-grown meat. 3D Bioprinting: iPSCs can be directed to differentiate into cell types of interest, such as skin, heart, or liver cells, which are then incorporated into bioinks. Wildlife Conservation and De-extinction Projects: iPSCs are being used in wildlife conservation and de-extinction projects. For example, Colossal Biosciences is using iPSC technology in an effort to achieve woolly mammoth de-extinction. #ipscells #celltherapy #drugdevelopment #research

16

🧬Global Induced Pluripotent Stem Cell (iPSC) Industry Report – Market Size, Trends, & Forecasts, 2024 - https://lnkd.in/esH83uh Today, iPSCs are being utilized across a diverse range of applications, including: Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease. Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models “in a dish”. Drug Development and Discovery:iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery. Personalized Medicine: The use of techniques such as CRISPR enable precise, directed creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies is adding a new dimension to personalized medicine. Toxicology Testing: iPSCs can be used for toxicology screening, which is the use of iPSCs or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells. Tissue Engineering: iPSCs can be seeded onto scaffolds made from biocompatible materials. These scaffolds mimic the structure and properties of the target tissue and can provide a supportive environment for cell growth and differentiation. Organoid Production: iPS cells can be coaxed to self-organize into 3D structures called organoids, which mimic the structure and function of organs. Organoids can be used for studying organ development, modeling diseases, and testing drugs. Gene Editing: iPSCs can be genetically modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic changes. These edited iPS cells can then be differentiated into the desired cell type for transplantation or disease modeling. Research Tools: iPSCs and iPSC-derived cell types are being widely used within a diverse range of basic and applied research applications. Stem Cell Banking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors. Cultured Meat Production: iPSCs are being utilized in clean meat production by serving as the cellular foundation for the creation of lab-grown meat. 3D Bioprinting: iPSCs can be directed to differentiate into cell types of interest, such as skin, heart, or liver cells, which are incorporated into bioinks. Wildlife Conservation and De-extinction Projects: iPSCs are being used in wildlife conservation and de-extinction projects. For example, Colossal Biosciences is using iPSC technology in an effort to achieve woolly mammoth de-extinction. #ipscells #celltherapy #drugdevelopment #research

61

Key Strategies for Positioning Cell Therapy CDMO Services – Size & Specificity - https://lnkd.in/eYA72dHX A contract development and manufacturing organization (CDMO), is a company that serves cell therapy companies on a contract basis. Common cell therapy CDMO services include cell therapy product development, manufacturing, clinical trial support, and commercial supply. CDMOs allows cell therapy companies to outsource aspects of their business, which can support: 1. Scalability 2. Speed to market 3. Adding technical expertise without overhead costs 4. Cost efficiencies Over the past several years, the biopharmaceutical industry has witnessed an increasing number of contract suppliers taking on the CDMO acronym to identify their ability to assist at the development stage of drug manufacturing. #cdmo #celltherapy #genetherapy #advancedtherapies

4

Preterm birth rates in India stand at approximately 13.2%, a statistic that demands urgent attention. Explore how Shimadzu's latest research application leverages multi-omics analysis to address this critical issue. #PretermBirth #MultiOmics #HealthcareInnovation #Shimadzu

15

2 Comments